Moderna Says Its COVID-19 Vaccine Is Safe and Effective in 12- to 17-Year-Olds

Moderna Says Its COVID-19 Vaccine Is, Safe and Effective, in 12- to 17-Year-Olds.

On Tuesday, Moderna announced the results of their Phase 2 trial of the administration of their COVID-19 vaccine to children ages 12 to 17.

.

According to results involving 3,732 children in the United States, their vaccine produces an immune response to COVID-19.

That immune response was found to be equivalent to the immune response produced in adults.

.

Moderna’s results in the children were “consistent with a vaccine efficacy of 100%.”.

The vaccine was found to be 93 percent effective at preventing mild cases of COVID-19 after one dose.

.

These mild cases only involved one symptom of COVID-19, rather than two or more.

.

No significant safety concerns were identified: only mild side effects after the second dose such as headache, fatigue, muscle pain, pain at the injection site and chills.

Moderna plans to submit their findings and a request for authorization to the U.S. Food and Drug Administration in early June.

.

Currently, Pfizer’s COVID-19 vaccine is the only one to have gained emergency use authorization from the FDA to include 12- to 15-year-olds